SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥144.43+CN¥1.54 (+1.08%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.0% below the high.
Loading market information…
SHZ · 300529.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jafron Biomedical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jafron Biomedical Co.,Ltd.’s forward annual dividend is CN¥0.52 per share, paid annual. The forward yield is 2.93% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Jafron Biomedical Co.,Ltd.’s next earnings report is currently expected on Mar 26, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jafron Biomedical Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Apr 15, 2025 | CN¥0.04-80.0% vs estimate | CN¥480.00M-28.25% vs estimate |
|---|
| Q1 2025 | Apr 15, 2025 | CN¥0.23+27.78% vs estimate | CN¥549.00M0.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥144.43+CN¥1.54 (+1.08%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.0% below the high.
CN¥48.98+CN¥0.36 (+0.74%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.64% below the high.
HK$51.30+HK$0.65 (+1.28%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.69% below the high.
CN¥182.37+CN¥3.37 (+1.88%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
HK$32.68-HK$0.40 (-1.21%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.1% below the high.
HK$44.96-HK$0.10 (-0.22%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.52% below the high.
HK$81.25-HK$0.35 (-0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.91% below the high.
HK$38.10+HK$2.12 (+5.89%)
JD Health International Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.92% below the high.
